{'fraction_non_alphanumeric': 0.022727272727272728, 'fraction_numerical': 0.0, 'mean_word_length': 5.5390625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)].

The role of statins in the management of patients with coronary artery disease and those at risk for cardiovascular events is well established. Patients with symptomatic heart failure, however, have been excluded from past placebo-controlled trials with statins and, therefore, the benefits and risks of statins in the treatment of heart failure remain controversial. The Swedish-based Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was designed to clarify the role of statin therapy in treating patients with heart failure with systolic dysfunction. This issue of Cardiology Scientific Update reviews the late-breaking results of CORONA, as well as their implications on the efficacy and safety of statins in the broad patient population.